Shares of Biogen (BIIB) and Ionis Pharmaceuticals (IONS) were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results. The two companies said their treatment for infantile-onset spinal muscular atrophy demonstrated statistically significant improvement in certain motor functions, according to a Wall Street Journal report. Ionis shares jumped nearly 30 percent on the news. Biogen plans to submit for regulatory approval in the coming months.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.